Valuation: Intervacc AB

Market Cap 340M 34.5M 30.15M 28.34M 25.86M 48.54M 3.3B 48.55M 131M 1.68B 130M 127M 5.43B P/E 2026 *
-0.89x
P/E 2027 * -0.89x
Enterprise Value 251M 25.48M 22.26M 20.92M 19.09M 35.84M 2.44B 35.84M 96.91M 1.24B 95.67M 93.58M 4.01B EV / Sales 2026 *
12x
EV / Sales 2027 * 9.3x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week-1.21%
Current month-7.64%
1 month-13.21%
3 months-25.27%
6 months+6.41%
Current year+5.95%
1 week 0.95
Extreme 0.951
1.05
1 month 0.95
Extreme 0.951
1.14
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
23/02/25 Free

Chief Financial Officer

929,208 1.2269%
17/02/25 Buy

Chief Executive Officer

135,000 0.1783%
17/02/25 Sell

Chief Executive Officer

278,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-1.21%-3.07%-72.84% 34.5M
-0.07%+7.14%+53.95%+111.00% 74.27B
-1.22%-0.42%+34.77%+77.07% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
+0.56%-1.94%-17.32%+366.25% 26.38B
-0.21%+5.37%+2.75%-2.08% 25.34B
+1.62%+4.84%+27.01%-8.05% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+0.87%-3.73%+159.95%+327.53% 15.17B
-0.86%+1.32%+44.51%+163.54% 14.41B
Average -0.25%+2.79%+33.03%+150.29% 28.01B
Weighted average by Cap. -0.19%+3.44%+36.47%+135.87%

Financials

2026 *2027 *
Net sales 21M 2.13M 1.86M 1.75M 1.6M 3M 204M 3M 8.1M 104M 8M 7.82M 335M 30M 3.04M 2.66M 2.5M 2.28M 4.28M 291M 4.28M 11.58M 149M 11.43M 11.18M 479M
Net income -82.45M -8.36M -7.31M -6.87M -6.27M -11.77M -800M -11.77M -31.82M -408M -31.41M -30.72M -1.32B -83.65M -8.49M -7.42M -6.97M -6.36M -11.94M -811M -11.94M -32.28M -414M -31.87M -31.17M -1.34B
Net Debt -89M -9.03M -7.89M -7.42M -6.77M -12.7M -863M -12.7M -34.34M -441M -33.91M -33.16M -1.42B -61M -6.19M -5.41M -5.08M -4.64M -8.71M -592M -8.71M -23.54M -302M -23.24M -22.73M -974M
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
23/09/26 SEK 0.9790 -1.90% 210,984
22/09/26 SEK 0.9980 -1.19% 274,229
21/09/26 SEK 1.010 0.00% 212,065
18/09/26 SEK 1.010 +1.41% 153,786
17/09/26 SEK 0.9960 +0.50% 79,996

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!